ScreenerHero

KAPA Kairos Pharma, Ltd.

AMEX · US · Healthcare · Biotechnology · kairospharma.com
0.8700USD-24.35%Mkt Cap: 2.95M $P/E: —

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the tr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.95M USD
Enterprise Value1.27M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.45M USD
Revenue/Share—
Last Price0.8700 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.25
PEG—
EV/EBITDA-0.22
EV/Revenue—
P/S—
P/B0.84
EPS (TTM)-1.96
EPS (Forward)-4.69
52W Range
0.84810% of range9.590
52W High9.590 USD
52W Low0.8481 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-85.90%
ROA-83.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.44M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-64.11%
Net Debt-2.63M USD
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity—
Current Ratio11.98
Quick Ratio9.91
Book Value/Sh1.37 USD
Cash/Share0.78 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateSep 1, 2026
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+704.6%
Target Range2.000 USD – 12.00 USD
2.000+704.6% to mean12.00
# Analysts2
Ownership
Shares Out.3.39M
Float2.25M
Insiders33.61%
Institutions7.82%
Short Interest
Short Ratio1.4d
Short % Float4.75%
Short % Out.3.38%
Shares Short114.39K
Short (prev mo.)52.03K
Technical
SMA 501.945 (-55.3%)
SMA 2003.507 (-75.2%)
Beta1.44
S&P 52W Chg15.77%
Avg Vol (30d)442.61K
Avg Vol (10d)97.87K
Technical Indicators
RSI (14)17.6
MACD-0.1794
MACD Signal-0.1185
MACD Hist.-0.0609
BB Upper2.116 USD
BB Middle1.640 USD
BB Lower1.165 USD
BB Width57.94%
ATR (14)0.2066 USD
Vol Ratio (20d)1.89x